Kairos Pharma’s (NYSEAMERICAN:KAPA – Get Free Report) lock-up period will end on Monday, March 17th. Kairos Pharma had issued 1,550,000 shares in its initial public offering on September 16th. The total size of the offering was $6,200,000 based on an initial share price of $4.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Wall Street Analysts Forecast Growth
Separately, D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a report on Wednesday, February 26th.
View Our Latest Stock Report on KAPA
Kairos Pharma Price Performance
About Kairos Pharma
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
Read More
- Five stocks we like better than Kairos Pharma
- Learn Technical Analysis Skills to Master the Stock Market
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Why Invest in 5G? How to Invest in 5G Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Are Dividend Achievers? An Introduction
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
